Pharming Group N.V. announced that the National Institute for Health and Care Excellence (NICE) has issued positive final guidance recommending Joenja® (leniolisib) for reimbursement and use within the National Health Service (NHS) in England and Wales.
The recommendation is for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) in adult and pediatric patients 12 years of age and older. Joenja is the first and only medicine specifically for APDS to be reimbursed within the NHS.
This positive guidance means Joenja is now available for use and funded in England through the Innovative Medicines Fund, and in Wales, it is expected to be available through the Welsh Health Specialised Services Committee. This marks a significant step in expanding patient access to Joenja in the UK.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.